Amgen stock falls as analysts mull over weight loss drug’s bone density data
Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the additional data suggests a new potential safety risk tied to the …